Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I open-label study of IPH4102 in relapsed/refractory KIR3DL2-positive cutaneous T-cell lymphoma
NL-OMON44047Phase 1Active, not recruiting
- Sponsor
- Innate Pharma
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of lacutamab in cutaneous T-cell lymphoma (CTCL), Sézary syndrome (SS), mycosis fungoides (MF) and 2 more (2 arms), sponsored by Innate Pharma. Primary endpoints: Dose-limiting toxicities and Adverse events and serious adverse events. Started Nov 2016; status: active, not recruiting.
02
Drugs
lacutamab
03
Conditions
cutaneous T-cell lymphoma (CTCL)Sézary syndrome (SS)mycosis fungoides (MF)CD30-positive cutaneous lymphoproliferative disorderanaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on NL-OMON44047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44047.